| Date | Time | Source | Headline | Symbol | Company |
| 07/11/2024 | 12:21PM | iHub Newswire | FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing | | |
| 08/06/2018 | 4:21PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 08/06/2018 | 4:01PM | PR Newswire (US) | Imprimis Pharmaceuticals Announces Second Quarter 2018 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 08/01/2018 | 7:30AM | PR Newswire (US) | Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection)... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/31/2018 | 7:30AM | GlobeNewswire Inc. | Imprimis Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 6, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/25/2018 | 7:31AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/18/2018 | 7:30AM | PR Newswire (US) | Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/02/2018 | 7:55PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/02/2018 | 7:49PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/02/2018 | 7:48PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/02/2018 | 7:45PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 07/02/2018 | 7:06PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 06/01/2018 | 7:02AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/30/2018 | 7:30AM | PR Newswire (US) | ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Ref... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/15/2018 | 5:47PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/15/2018 | 5:47PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/15/2018 | 4:01PM | PR Newswire (US) | Imprimis Pharmaceuticals Announces First Quarter 2018 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/15/2018 | 7:33AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/15/2018 | 7:30AM | PR Newswire (US) | Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 05/02/2018 | 7:30AM | GlobeNewswire Inc. | Imprimis Pharmaceuticals to Host its First Quarter 2018 Financial Report Conference Call and Webcast on May 15, 2018 at 4:30 ... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 04/30/2018 | 6:28PM | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 04/13/2018 | 8:01AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 04/12/2018 | 4:39PM | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 04/10/2018 | 7:30AM | PR Newswire (US) | Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (m... | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/27/2018 | 7:30AM | PR Newswire (US) | Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/12/2018 | 7:31AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/08/2018 | 4:31PM | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/08/2018 | 4:29PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/08/2018 | 4:01PM | PR Newswire (US) | Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |
| 03/07/2018 | 7:30AM | PR Newswire (US) | Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018 | NASDAQ:IMMY | Imprimis Pharmaceuticals, Inc. (delisted) |